Vidence and 2bPrecise Announce Strategic Partnership to Unleash the Power of Genomic Data in Precision Oncology
Vidence has selected the 2bPrecise™ platform, a precision medicine data delivery solution, to make it easier for its Consortium Fellows to unlock the true power of genomic data at the point of care and facilitate the advancement of precision oncology. Vidence’s proprietary SCIMON™ technology platform will seamlessly integrate with the 2bPrecise cloud-based platform delivering data-driven insights directly into the provider’s workflow to prompt an evidence-based choice of action.
Vidence and NTT DATA Announce Partnership to Deliver Predictive Analytics in Oncology
Vidence and NTT DATA Services, a global digital business and IT services leader, today announced a relationship to build advanced AI and ML algorithms to predict patient outcomes, enhance decision-making, and drive clinical trials to advance cancer research and treatment. This unique collaboration will utilize a combination of medical imaging scan, clinical and outcomes data to build a predictive model that will optimize treatment regimens.
Vidence, LLC Launched to Set Standard for High-Quality Cancer Data, Research and Analytics
Vidence, LLC, an oncology informatics company, was officially launched today as an independent entity to provide the world’s leading cancer researchers, innovators and providers with the most comprehensive clinical and genomic data and insights. Founded by leading members of the medical and technical communities, Vidence fills an evidence gap in oncology and helps pharmaceutical and biotech firms and other healthcare institutions accelerate the development of cancer treatments and optimize patient care.